Carisma Therapeutics Inc. is a biotechnology company focused on developing innovative cell-based therapies, primarily in immune-oncology.

# Company Overview: Carisma Therapeutics Inc.

**Business Focus:**  
Carisma Therapeutics Inc. is a biotechnology company that specializes in developing innovative cell-based therapies, focusing primarily on immune-oncology and potentially other therapeutic areas involving cellular medicine.

**Key Details:**  
- **Number of Employees:** Not explicitly provided in the document.
- **Number of Customers:** Not specified in the provided excerpt.
- **Revenue, Income, and Financials:**  
  - As of the fiscal year ending December 31, 2024, the company's total reported revenue and income are not detailed in the provided excerpt.  
  - The document contains references to financial statements included in the Original Filing, but specific figures for revenue, net income, or other financial metrics are not provided in this summary.

**Additional Company Information:**  
- **Stock Symbol:** CARM (Common Stock, $0.001 par value) listed on The Nasdaq Stock Market LLC.  
- **Market Capitalization (as of June 28, 2024):** Approximately $53.1 million.  
- **Stock Outstanding (as of March 26, 2025):** 41,788,096 shares.

**Operational Focus:**  
- The company engages in research and development of cellular therapies, particularly involving immune cells, such as macrophage-based treatments.
- They have collaborations and licensing agreements with academic institutions and pharmaceutical companies to develop and commercialize their therapies.

**Note:**  
Specific financial figures such as revenue, net income, or other financial performance metrics are not explicitly disclosed in the provided excerpt. The available information emphasizes corporate governance, executive compensation, stock ownership, and securities-related disclosures rather than detailed financial performance.

Carisma Therapeutics Inc. is a clinical-stage cell therapy company focused on developing innovative immunotherapies utilizing its CAR-M cell therapy platform to treat cancer and other serious diseases.

# Company Overview: Carisma Therapeutics Inc.

## Business Focus
Carisma Therapeutics Inc. is a clinical-stage cell therapy company that specializes in using its proprietary CAR-M (Chimeric Antigen Receptor Macrophage) cell therapy platform. The company's mission is to develop transformative immunotherapies aimed at treating cancer and other serious diseases. The technology harnesses engineered macrophages and monocytes, which are crucial components of the innate immune system, to target and attack tumor cells.

## Key Technologies
- **CAR-M Cell Therapy Platform**: Redirects macrophages to recognize and target specific tumor-associated antigens (TAAs) on cancer cells.
- **Product Candidates**:
  - **CT-0508**: The first CAR-Macrophage in clinical trials for solid tumors over-expressing HER2, currently undergoing a Phase 1 clinical trial in the United States.
  - **CT-0525**: A CAR-Monocyte intended to treat solid tumors over-expressing HER2. FDA clearance for the IND was received in November 2023, with the first patient expected to be treated in Q2 2024.

## Organizational Structure
- **Number of Employees**: As of December 31, 2023, Carisma has 107 full-time employees, including 33 employees holding M.D. or Ph.D. degrees, primarily engaged in research and development.
- **Clinical Sites**: The company has initiated clinical trials at seven major cancer research centers in the United States.

## Financial Overview
- **Revenue**: The company has not generated revenue from product sales to date and relies on funding from various sources, including collaborations and investments.
- **Net Loss**: For the years ended December 31, 2023, and 2022, the company reported net losses of $86.9 million and $61.2 million, respectively.
- **Funding**: Carisma has raised funds through sales of preferred stock, collaboration agreements (e.g., with Moderna), and convertible debt financing. As of December 31, 2023, it had cash and cash equivalents totaling $77.6 million, which it believes will sustain operations into Q3 2025.

## Strategic Partnerships
Carisma has established a significant collaboration with Moderna, focusing on the development of in vivo CAR-M therapeutics. This partnership allows the company to leverage Moderna's mRNA/lipid nanoparticle technology for its product candidates, expanding its research and development potential.

## Future Outlook
Carisma aims to continue developing therapies targeting solid tumors with a focus on timely clinical developments and collaborations while managing its operational expenses. The company is navigating various challenges associated with the clinical development landscape, including regulatory hurdles and the need for further financing. 

*The company aims to position itself as a leader in macrophage- and monocyte-based cell therapies, with expectations of clinical milestones and potential product commercialization.*

Carisma Therapeutics Inc.

10-K / April 29, 2025

10-K / April 1, 2024

10-K / April 29, 2025

Company Overview: Carisma Therapeutics Inc.